Patents Assigned to Monash University
-
Publication number: 20050026225Abstract: A method for diagnosing early stage renal disease and/or renal complications of a disease in which intact albumin is an indicator of the renal disease and/or complications. The method includes an isolated intact protein, an anti-intact protein antibody thereto, and methods for preparing the same.Type: ApplicationFiled: August 20, 2004Publication date: February 3, 2005Applicant: MONASH UNIVERSITYInventor: Wayne Comper
-
Publication number: 20040265285Abstract: The present disclosure provides methods for the treatment and potential alleviation of autoimmune diseases and allergies in a patient. This is accomplished by deleting at least most of the existing T cell population and reactivating the thymus. Optionally, hematopoietic stem cells, autologous, syngeneic, allogeneic or xenogeneic, are delivered to increase the speed of regeneration of the patient's immune system and to supply normal T cells to the patient or to replace existing aberrant T cells. In some embodiments, the hematopoietic stem cells are CD34+. The patient's thymus is reactivated by disruption of sex steroid mediated signaling to the thymus. In some embodiments, this disruption is created by administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines or combinations thereof.Type: ApplicationFiled: December 30, 2003Publication date: December 30, 2004Applicant: Monash UniversityInventor: Richard L. Boyd
-
Publication number: 20040259803Abstract: The present disclosure provides methods for prevention and/or treatment of disease or illness in a patient by stimulating a patient's immune system through reactivation of the thymus. The patient's thymus is reactivated by interruption or ablation of sex steroid mediated signaling to the thymus, such as through the administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines, anti-androgens, anti-estrogens, selective estrogen receptor modulators (SERMS), selective androgen receptor modulators (SARMS), aromatase inhibitors, or various combinations thereof. Non-limiting examples of illnesses or diseases that may be prevented or treated using the methods of the invention are those caused by viruses, bacteria, fungi, parasites, prions, cancers, allergens, asthma-inducing agents, or “self” proteins and other antigens which cause autoimmune disease.Type: ApplicationFiled: December 30, 2003Publication date: December 23, 2004Applicant: Monash UniversityInventor: Richard L. Boyd
-
Publication number: 20040258672Abstract: The present disclosure provides methods for inducing tolerance in a recipient to a mismatched graft of an organ, tissue and/or cells. By reactivating the recipient's thymus and providing hematopoietic stem cells from the donor, the previously “foreign” matter becomes recognized as “self” in the recipient and is not rejected. The patient's T cell population is depleted. In some embodiments, the hematopoietic stem cells are CD34+. The recipient's thymus is reactivated by disruption of sex steroid mediated signaling to the thymus. In some embodiments, this disruption is created by administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines or combinations thereof.Type: ApplicationFiled: December 30, 2003Publication date: December 23, 2004Applicant: Monash UniversityInventor: Richard L. Boyd
-
Publication number: 20040241842Abstract: The present disclosure provides methods for enhancing the response of a patient's immune system to vaccination. This is accomplished by reactivating the thymus. Optionally, hematopoietic stem cells, autologous, syngeneic, allogeneic or xenogeneic, are delivered to increase the speed of regeneration of the patient's immune system. In one embodiment the hematopoietic stem cells are CD34+. The patient's thymus is reactivated by disruption of sex steroid mediated signaling to the thymus. In one embodiment, this disruption is created by administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines or combinations thereof.Type: ApplicationFiled: December 30, 2003Publication date: December 2, 2004Applicant: Monash UniversityInventor: Richard L. Boyd
-
Publication number: 20040219234Abstract: Method for obtaining tannin by extracting plant resources with mangrove, acacia, pine, eucalyptus, oak, hemlock and the like with lower alcohol or lower alcohol/water, or extracting outer bark of radiata pine (Pinus radiata) with water, lower alcohol or lower alcohol/water, and an adhesive containing said extracted substance for adhering woody materials such as veneer.Type: ApplicationFiled: May 28, 2004Publication date: November 4, 2004Applicants: KABUSHIKI KAISHA WOOD ONE T/A WOOD ONE CO., LTD., MONASH UNIVERSITYInventors: Yusho Nakamoto, Toshihiko Tsunoda, Keiko Ono, Naoko Kaeyama, Yoshikazu Yazaki, Huijian Jiang, Frank Lawson, Peter Heinz Theodore Uhlherr
-
Publication number: 20040209805Abstract: The present invention relates to pharmaceutical compositions for the treatment and/or prophylaxis of disease associated with fibrosis in a vertebrate, said composition comprising at least one activin antagonist, and optionally a pharmaceutically acceptable carrier, adjuvant and/or diluent. The invention also relates to methods of treatment of disease associated with fibrosis in a vertebrate, as well as methods for diagnosing such conditions, and kits therefor.Type: ApplicationFiled: January 12, 2004Publication date: October 21, 2004Applicants: BIOA Pty Limited, Monash UniversityInventors: David Phillips, David de Kretser, William Sievert, Shane Patella, Joseph Smolich, David McGaw, Paul Fennessy
-
Patent number: 6787530Abstract: A composition when used as an analgesic comprising a metabolite of a compound of Formula II wherein R1 is H or Me, R2 is OH, R3 is H; or R2 and R3, taken together, are O; R4 is H or Me, R5 and R6, taken together, are O; R7 is H or Me, R8=H, OH, OAc, SH, SAc, Cl, Br, F together with a pharmaceutically acceptable diluent.Type: GrantFiled: November 20, 1998Date of Patent: September 7, 2004Assignee: Monash UniversityInventors: Colin Stanley Goodchild, Raymond Nadeson
-
Publication number: 20040146469Abstract: The invention relates to a method for treatment or prophylaxis of a disease or condition in an animal comprising administering to a mucosal membrane of said animal in need of such treatment a therapeutically effective amount of a drug delivery system comprising at least one physiologically active agent or prodrug thereof and at least one penetration enhancer selected from safe ester sunscreens.Type: ApplicationFiled: January 20, 2004Publication date: July 29, 2004Applicant: Monash UniversityInventors: Barry Lenard Reed, Timothy Matthias Morgan, Barrie Charles Finnin
-
Publication number: 20040106155Abstract: A method is disclosed for diagnosing early stage of a disease in which an intact protein found in urine is an indicator of the disease, followed by early drug intervention to prevent and treat the disease are also disclosed. The drug treatment involves the use of a lysosome activating compound.Type: ApplicationFiled: November 26, 2003Publication date: June 3, 2004Applicant: MONASH UNIVERSITYInventor: Wayne D. Comper
-
Publication number: 20040096405Abstract: The present invention provides a topical drug delivery system which comprises: a therapeutically effective amount of an anti-alopecia agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and a volatile liquid. The invention also provides a method for administering at least one systemic acting anti-alopecia agent to an animal which comprises applying an effective amount of the anti-alopecia agent in the form of the drug delivery system of the present invention.Type: ApplicationFiled: August 8, 2003Publication date: May 20, 2004Applicant: Monash UniversityInventors: Nora Yat Knork Chew, Barry Leonard Reed, Timothy Matthias Morgan, Barrie Charles Finnin
-
Publication number: 20040081684Abstract: The present invention provides a topical drug delivery system which comprises: a therapeutically effective amount of an antifungal agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and a volatile liquid. The invention also provides a method for administering at least one systemic acting antifungal agent to an animal which comprises applying an effective amount of the antifungal agent in the form of the drug delivery system of the present invention.Type: ApplicationFiled: August 20, 2003Publication date: April 29, 2004Applicant: Monash UniversityInventors: Nora Yat Knork Chew, Barry Leonard Reed, Timothy Matthias Morgan, Barrie Charles Finnin
-
Publication number: 20040037816Abstract: The present disclosure provides methods for inducing tolerance in a recipient to a mismatched graft of an organ, tissue and/or cells. By reactivating the recipient's thymus and providing hematopoietic stem cells from the donor, the previously “foreign” matter becomes recognized as “self” in the recipient and is not rejected. The patient's T cell population is depleted. In some embodiments, the hematopoietic stem cells are CD34+. The recipient's thymus is reactivated by disruption of sex steroid mediated signaling to the thymus. In some embodiments, this disruption is created by administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines or combinations thereof.Type: ApplicationFiled: April 18, 2003Publication date: February 26, 2004Applicant: Monash UniversityInventor: Richard Boyd
-
Publication number: 20040037817Abstract: The present disclosure provides methods for the treatment and potential alleviation of autoimmune diseases and allergies in a patient. This is accomplished by deleting at least most of the existing T cell population and reactivating the thymus. Optionally, hematopoietic stem cells, autologous, syngeneic, allogeneic or xenogeneic, are delivered to increase the speed of regeneration of the patient's immune system and to supply normal T cells to the patient or to replace existing aberrant T cells. In some embodiments, the hematopoietic stem cells are CD34+. The patient's thymus is reactivated by disruption of sex steroid mediated signaling to the thymus. In some embodiments, this disruption is created by administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines or combinations thereof.Type: ApplicationFiled: April 18, 2003Publication date: February 26, 2004Applicant: Monash UniversityInventor: Richard Lennox Boyd
-
Publication number: 20040028725Abstract: The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of a hormone; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid.Type: ApplicationFiled: May 2, 2003Publication date: February 12, 2004Applicant: Monash UniversityInventors: Timothy Matthias Morgan, Margarita Vladislavova Bakalova, Karthryn Traci-Jane Klose, Barrie Charles Finnin, Barry Leonard Reed
-
Publication number: 20040028625Abstract: The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an analgesic; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting analgesic to an animal which comprises applying an effective amount of the analgesic in the form of the drug delivery system of the present invention.Type: ApplicationFiled: May 2, 2003Publication date: February 12, 2004Applicant: Monash UniversityInventors: Kathryn Traci-Jane Klose, Felicia Maria Colagrande, Timothy Matthias Morgan, Barrie Charles Finnin, Barry Leonard Reed
-
Publication number: 20040018180Abstract: The present disclosure provides methods for enhancing the response of a patient's immune system to vaccination. This is accomplished by reactivating the thymus. Optionally, hematopoietic stem cells, autologous, syngeneic, allogeneic or xenogeneic, are delivered to increase the speed of regeneration of the patient's immune system. In one embodiment the hematopoietic stem cells are CD34+. The patient's thymus is reactivated by disruption of sex steroid mediated signaling to the thymus. In one embodiment, this disruption is created by administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines or combinations thereof.Type: ApplicationFiled: April 18, 2003Publication date: January 29, 2004Applicant: Monash UniversityInventor: Richard Lennox Boyd
-
Publication number: 20040013620Abstract: The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an antiParkinson agent; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting antiParkinson agent to an animal which comprises applying an effective amount of the antiParkinson agent in the form of the drug delivery system of the present invention.Type: ApplicationFiled: May 2, 2003Publication date: January 22, 2004Applicant: Monash UniversityInventors: Kathryn Traci-Jane Klose, Ngan Thi Kim Tran, Timothy Matthias Morgon, Barrie Charles Finnin, Barry Leonard Reed
-
Publication number: 20040013621Abstract: The present invention provides a transdermal drug delivery system which comprises: a therapeutically effective amount of an antiemetic; at least one dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen ester; and at least one volatile liquid. The invention also provides a method for administering at least one systemic acting antiemetic thereof to an animal which comprises applying an effective amount of the antiemetic in the form of the drug delivery system of the present invention.Type: ApplicationFiled: May 2, 2003Publication date: January 22, 2004Applicant: Monash UniversityInventors: Kathryn Traci-Jane Klose, Jianwen Zhou, Timothy Matthias Morgan, Barrie Charles Finnin, Barry Leonard Reed
-
Publication number: 20040013641Abstract: The present disclosure provides methods for gene therapy utilizing hematopoietic stem cells, lymphoid progenitor cells, and/or myeloid progenitor cells. The cells are genetically modified to provide a gene that is expressed in these cells and their progeny after differentiation. In one embodiment the cells contain a gene or gene fragment that confers to the cells resistance to HIV infection and/or replication. The cells are administered to a patient in conjunction with treatment to reactivate the patient's thymus. The cells may be autologous, syngeneic, allogeneic or xenogeneic, as tolerance to foreign cells is created in the patient during reactivation of the thymus. In an embodiment the hematopoictic stem cells are CD34+. The patient's thymus is reactivated by disruption of sex steroid mediated signaling to the thymus. In another embodiment, this disruption is created by administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines or combinations thereof.Type: ApplicationFiled: April 18, 2003Publication date: January 22, 2004Applicant: Monash UniversityInventor: Richard Boyd